GC203 TIL for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced cancer that has spread and standard treatments (chemotherapy, radiation, targeted therapy, immunotherapy, or surgery) have failed.
- You have a tumor that can be safely removed or biopsied to create the TIL treatment.
- You have at least one tumor that can be measured on scans and you are well enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges.
- You are not pregnant, breastfeeding, and willing to use effective birth control if sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This early-stage trial tests a type of immune cell treatment (TILs) made from your tumor to treat advanced solid cancers. It may help if standard treatments have failed or aren’t an option, but you must be able to provide enough tumor tissue for cell collection.
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.